Fig. 1From: Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control studyComparison of the concurrent and no concurrent androgen deprivation therapy (ADT) groups with respect to biochemical recurrence (BCR)-free survival form the date of radiotherapy.The estimated 5-year BCR-free survival rates for the no concurrent and concurrent ADT groups were 53.9% and 66.1% (p = 0.016), respectivelyBack to article page